Trial Profile
An Open-label, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI9253, a Recombinant Newcastle Disease Virus Encoding Interleukin-12, in Combination With Durvalumab in Participants With Select Advanced/Metastatic Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; MEDI 9253 (Primary)
- Indications Colorectal cancer; Malignant melanoma; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 07 Sep 2023 Planned End Date changed from 27 Feb 2025 to 26 Nov 2024.
- 07 Sep 2023 Planned primary completion date changed from 27 Feb 2025 to 26 Nov 2024.
- 08 Mar 2023 Results (n=40) assessing the safety, pharmacokinetics and efficacy of MEDI9253 in combination with durvalumab in patients with advanced/metastatic solid tumors, presented at the 21st International Congress on Targeted Anticancer Therapies.